Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANEXSIA 5/325 vs AKNE-MYCIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen is a para-aminophenol derivative with analgesic and antipyretic effects, primarily through central COX-2 inhibition and activation of descending serotonergic pathways.
Erythromycin, a macrolide antibiotic, binds to the 50S subunit of bacterial ribosomes and inhibits protein synthesis by blocking translocation of peptidyl-t RNA. Topically, it reduces Propionibacterium acnes colonization and exhibits anti-inflammatory properties.
Management of moderate to moderately severe pain where an opioid analgesic is appropriate
Topical treatment of acne vulgaris
1-2 tablets orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Topical application of 2% solution twice daily to affected areas.
Oxycodone: terminal half-life 3.2-4.3 hours (immediate-release); prolonged in hepatic impairment. Acetaminophen: terminal half-life 2-3 hours (therapeutic doses); prolonged in hepatic impairment or overdose.
2-3 hours (normal renal function); up to 24-36 hours in severe renal impairment
Hydrocodone: primarily hepatic via CYP3A4 and CYP2D6 to active metabolites (hydromorphone). Acetaminophen: hepatic metabolism via conjugation (glucuronidation, sulfation) and CYP2E1-mediated oxidation to toxic NAPQI.
Not systemically absorbed to a clinically significant degree after topical application. If absorbed, erythromycin is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4.
Oxycodone: renal excretion of metabolites (conjugated and unconjugated) and parent drug; ~10% excreted unchanged. Acetaminophen: renal excretion of metabolites (glucuronide and sulfate conjugates); ~2-4% excreted unchanged.
Primarily renal (60-80% unchanged); minor biliary/fecal (15-30%)
Oxycodone: 38-45% bound to albumin and alpha-1-acid glycoprotein. Acetaminophen: 10-25% bound to albumin at therapeutic concentrations.
Bound primarily to albumin (10-20%)
Oxycodone: Vd 2.0-3.0 L/kg; distributes extensively into tissues. Acetaminophen: Vd 0.8-1.0 L/kg; relatively uniform distribution.
0.2-0.3 L/kg, indicating limited extravascular distribution (primarily extracellular fluid)
Oxycodone: oral bioavailability 60-87% (immediate-release). Acetaminophen: oral bioavailability 88-98% (therapeutic doses).
Topical: 2-5% (minimal systemic absorption); oral: 75-85%
GFR 30-50 m L/min: use with caution, increase dosing interval to every 6 hours; GFR <30 m L/min: avoid use due to hydrocodeone accumulation.
No dosage adjustment required for topical use; systemic absorption negligible.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor; Child-Pugh C: contraindicated.
No dosage adjustment required for topical use; systemic absorption negligible.
Not recommended for children under 18 years due to risk of respiratory depression.
Safety and efficacy not established in children under 12 years; for age ≥12 years, same as adult dosing.
Start with lowest dose (1 tablet every 6 hours), monitor renal and hepatic function, and avoid in frail elderly due to increased fall and cognitive impairment risk.
No specific adjustments; use with caution due to potential increased skin sensitivity.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and hepatotoxicity from acetaminophen overdose.
None
Risk of opioid addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity; adrenal insufficiency; severe hypotension; gastrointestinal obstruction; seizure; and serotonin syndrome.
For external use only; avoid contact with eyes, mouth, and mucous membranes. May cause skin irritation, burning, stinging, or dryness. Reported cases of pseudomembranous colitis with topical use (rare). Use with caution in patients with hepatic impairment if significant systemic absorption occurs. Cross-resistance with other macrolides may develop. Use during pregnancy only if clearly needed (category B).
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known or suspected paralytic ileus; severe hepatic impairment; and concurrent use of MAOIs within 14 days.
Hypersensitivity to erythromycin or any component of the formulation. Concurrent use with pimozide or ergot alkaloids (potential for QT prolongation and ergotism, though systemic absorption low).
Avoid alcohol. Grapefruit juice may enhance side effects; limit intake. Take with food to reduce gastrointestinal discomfort.
No specific food interactions. Take with or without food. Avoid excessive intake of spicy or greasy foods, which may exacerbate acne.
First trimester: Associated with increased risk of neural tube defects and cardiovascular malformations; avoid use. Second and third trimesters: Chronic exposure may cause fetal renal toxicity, oligohydramnios, and premature closure of ductus arteriosus. Use only if clearly needed.
Akne-Mycin (erythromycin topical) is Pregnancy Category B. No evidence of teratogenicity in animal studies; adequate human studies are lacking. Systemic absorption is minimal with topical use, but risk cannot be completely excluded. First trimester: low risk, but use only if clearly needed. Second and third trimesters: generally considered safe with minimal systemic exposure.
Paracetamol and hydrocodone are excreted in breast milk. M/P ratio: paracetamol ~1.0, hydrocodone ~1.0-2.0. Use with caution; monitor infant for drowsiness and respiratory depression. Consider risk of infant sedation with long-term use.
Erythromycin is excreted in human milk in small amounts. Topical Akne-Mycin results in negligible systemic absorption, making significant infant exposure unlikely. M/P ratio not reported for topical use; oral erythromycin M/P ratio is approximately 0.5. Caution is advised, but use is generally compatible with breastfeeding.
Increased clearance in pregnancy may require dose adjustment. Monitor for pain control and adverse effects; no fixed dose change recommended. Consider lower starting dose due to potential fetal risks. Avoid chronic use; taper if possible.
No dose adjustment necessary. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) are not clinically relevant for topical Akne-Mycin due to minimal systemic absorption. Apply as directed regardless of pregnancy trimester.
ANEXSIA 5/325 contains hydrocodone 5 mg and acetaminophen 325 mg. Maximum acetaminophen dose from all sources should not exceed 4 g/day in adults; avoid in severe hepatic impairment. Hydrocodone is a Schedule II controlled substance with abuse potential; monitor for respiratory depression, especially in opioid-naive patients. Use with caution in patients with COPD, sleep apnea, or increased intracranial pressure. Consider naloxone co-prescription for high-risk patients. For acute pain, limit duration to 3-7 days.
Akne-Mycin (erythromycin topical) is effective for mild to moderate acne vulgaris. It can be combined with benzoyl peroxide to reduce antibiotic resistance. Avoid use with other topical erythromycin products to prevent overuse. Monitor for local skin reactions like erythema, scaling, or itching.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not consume alcohol or other sedatives (e.g., benzodiazepines) while taking this medication.,Avoid other products containing acetaminophen (e.g., Tylenol, cold remedies) to prevent liver damage.,This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Store securely out of reach of others; dispose of unused medication via drug take-back programs.,Seek emergency help if you have trouble breathing, severe drowsiness, or signs of allergic reaction.
Apply a thin layer to affected areas once or twice daily as directed.,Wash skin gently with mild soap and pat dry before application.,Avoid contact with eyes, mouth, and mucous membranes.,Do not use more often than prescribed; overuse can increase irritation.,Inform your doctor if you develop severe redness, peeling, or discomfort.,Use sunscreen daily as this medication may increase sun sensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANEXSIA 5/325 vs AKNE-MYCIN, answered by our medical review team.
ANEXSIA 5/325 is a Opioid Analgesic Combination that works by Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen is a para-aminophenol derivative with analgesic and antipyretic effects, primarily through central COX-2 inhibition and activation of descending serotonergic pathways.. AKNE-MYCIN is a Topical Antibiotic that works by Erythromycin, a macrolide antibiotic, binds to the 50S subunit of bacterial ribosomes and inhibits protein synthesis by blocking translocation of peptidyl-t RNA. Topically, it reduces Propionibacterium acnes colonization and exhibits anti-inflammatory properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANEXSIA 5/325 and AKNE-MYCIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANEXSIA 5/325 is: 1-2 tablets orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. The standard adult dose of AKNE-MYCIN is: Topical application of 2% solution twice daily to affected areas.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANEXSIA 5/325 and AKNE-MYCIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANEXSIA 5/325 is classified as Category C. First trimester: Associated with increased risk of neural tube defects and cardiovascular malformations; avoid use. Second and third trimesters: Chronic exposure may cause fetal re. AKNE-MYCIN is classified as Category C. Akne-Mycin (erythromycin topical) is Pregnancy Category B. No evidence of teratogenicity in animal studies; adequate human studies are lacking. Systemic absorption is minimal with . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.